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Abstract
Background: Long-term survival outcome of critically ill patients is important in assessing effectiveness of new treatments
and making treatment decisions. We developed a prognostic model for estimation of long-term survival of critically ill
patients.
Methodology and Principal Findings: This was a retrospective linked data cohort study involving 11,930 critically ill
patients who survived more than 5 days in a university teaching hospital in Western Australia. Older age, male gender, co-
morbidities, severe acute illness as measured by Acute Physiology and Chronic Health Evaluation II predicted mortality, and
more days of vasopressor or inotropic support, mechanical ventilation, and hemofiltration within the first 5 days of intensive
care unit admission were associated with a worse long-term survival up to 15 years after the onset of critical illness. Among
these seven pre-selected predictors, age (explained 50% of the variability of the model, hazard ratio [HR] between 80 and
60 years old=1.95) and co-morbidity (explained 27% of the variability, HR between Charlson co-morbidity index 5 and
0=2.15) were the most important determinants. A nomogram based on the pre-selected predictors is provided to allow
estimation of the median survival time and also the 1-year, 3-year, 5-year, 10-year, and 15-year survival probabilities for a
patient. The discrimination (adjusted c-index=0.757, 95% confidence interval 0.745–0.769) and calibration of this
prognostic model were acceptable.
Significance: Age, gender, co-morbidities, severity of acute illness, and the intensity and duration of intensive care therapy
can be used to estimate long-term survival of critically ill patients. Age and co-morbidity are the most important
determinants of long-term prognosis of critically ill patients.
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Introduction
Demand for intensive care unit (ICU) services is increasing [1],
and at a rate that is higher than the average for all health care
services [2]. Increase in treatment and monitoring technology,
patients’ expectations, and ageing population all contribute to this
increased demand for intensive care services [1]. Indeed, intensive
care is increasingly being provided to older and sicker patients,
whom in the past were not treated in intensive care [3]. Intensive
care services accounted for 10% of the US$2.1 trillion total health
expenditures on health care in the United States in 2006 [4] and
has been estimated to cost more than £700 million in the United
Kingdom in 1999 [5]. The cost of intensive care services coupled
with increasing demand provides the rationale for improved
modelling of outcomes of critically ill patients.
Long-term survival after critical illness is increasingly being
recognized as an important outcome in assessing effectiveness of
new therapy [6]. In order to control for confounding and bias in
assessing long-term survival of critically ill patients in a clinical
trial, a risk adjustment tool that can objectively estimate long-term
survival is essential. From a clinical perspective, many patients and
clinicians are also interested in knowing the long-term survival
outcome after critical illness, in addition to other information such
as burden of treatment and quality of life after recovery, when
making treatment decisions in the ICU. Although many clinicians
may foretell patient hospital survival outcome more accurately
than some objective prognostic models [7], treatment decisions
made by clinicians do vary considerably with their practice style
and work experience [8–10]. The strategy of continuing intensive
treatment for all patients until death will reduce the need for
patients and clinicians to make difficult treatment decisions and
may improve the survival time of some. This strategy is, however,
expensive and undesirable by imposing excessive burden of
treatment on those who have a very poor prognosis [11]. For
example, initiating acute renal replacement therapy in critically ill
patients with less than 10% probability of 6-month survival was
estimated to cost US$274,000 (£137,000) per quality-adjusted life
year saved [12].
The SUPPORT investigators from the United States and
Wright et al. from the United Kingdom published two prognostic
models that were based on age, severity of acute illness and
admission diagnosis to estimate 6-month and 5-year survival of
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model is, however, limited by its ability to classify 5-year survival
probabilities only into three risk categories when the calculated
risk score is either ,70, 70–80, or .80 [14]. This model also did
not consider the potential effect of detailed co-morbidity data on
long-term survival of critically ill patients beyond the usual
assessment included in the Acute Physiology and Chronic Health
Evaluation (APACHE) score [14,15]. There is currently no
prognostic model that is available to estimate the survival of
critically ill patients beyond 5 years after the onset of critical
illness. Furthermore, the relative importance of age, co-morbidity,
and severity of acute illness in determining long-term prognosis of
critically ill patients also remains unknown. In this study we
examined the long-term survival of 11,930 critically ill adult
patients who survived at least 5 days and developed a new
prognostic model (Predicted Risk, Existing Diseases, and Intensive
Care Therapy: the PREDICT model) to estimate their median
survival time and long-term survival probabilities.
Methods
The characteristics of the cohort
This cohort study utilized the clinical database of the ICU at
Royal Perth Hospital (RPH) in Western Australia. RPH is the
largest tertiary university teaching hospital in Western Australia
and the 22-bed ICU admits patients of all specialties except liver
transplantation and captures over 40% of all critically ill patients
in Western Australia. The database analyzed in this study includes
details of all ICU admissions between 1989 and 2002, including
demographic factors, admission diagnosis, admission source,
severity of acute illness as measured by APACHE II scores based
on the worst first 24-hour ICU data [15], daily organ failure
assessment and supportive therapy required [16], and ICU and
hospital survival outcome.
In this study the patients with a diagnosis excluded from the
original APACHE II cohort (e.g. coronary artery graft surgery,
burns, snake bite)[15], those who resided outside Western
Australia at the time of ICU admission (who could not be
followed for survival), readmissions after the first ICU readmission,
patients who were younger than 16 years old, and patients who
did not survive more than 5 days during their hospitalization of
the index ICU admission were excluded. The data were reviewed
for internal consistency annually, and there were no patients with
missing hospital mortality data. Some of the other details of this
cohort have been described in our previous publications [16–18].
The ICU clinical database was linked to the Western Australian
hospital morbidity and mortality databases using probabilistic
matching [16], providing information on patients’ co-morbidities
as recorded in all private and public hospital admissions including
any prior ICU admissions up to 5 years before the index ICU
admission. A relatively long five-year ‘look back’ period was
chosen in this study to capture all existing co-morbidities of each
patient. We ascertained the presence of co-morbidities in the
Charlson co-morbidity index (Table 1) using the published ICD-
9-CM and ICD-10-AM coding algorithms [16,19]. We did not
assign a co-morbidity to a patient if that condition was diagnosed
during the hospitalization of the index ICU admission. The
proportions of invalid (false positive) and missed links (false
negatives) between Western Australian hospital morbidity and
mortality databases were evaluated several years ago, and both
false positives and negatives were estimated to be 0.11% [20].
The survival status of the patients was assessed on 31 December
2003 and the length of follow up ranged from 1 year to 15 years
with an average of 6 years. Western Australia is geographically
isolated and has a very low rate of emigration (,0.03% in
2002)[16], and as such, lost to long-term survival follow-up by the
Western Australian mortality database is likely to be very low. The
data analyzed had the patient name and address removed and the
study was approved by the RPH Ethics Committee and the
Western Australian Confidentiality of Health Information Com-
mittee (CHIC).
Development of the model
The prognostic model was fitted using Cox proportional
hazards regression [21], restricting predictors to factors that were
likely to be important predictors of long-term survival of
hospitalized patients [13,14,22,23]. These pre-selected factors
included age [14,22], gender [22], APACHE II predicted
mortality risk [13–15], Charlson co-morbidity index [19,23], days
of mechanical ventilation, acute renal replacement therapy or
hemofiltration, and vasopressor or inotropic therapy during the
first 5 days of the index ICU admission [13]. The APACHE II
predicted mortality was chosen as a measure of severity of acute
illness because it is widely used and summarizes the diagnosis,
acute physiologic derangement within the first 24 hours of ICU
admission, severe co-morbidities, and whether the ICU admission
is after elective or emergency surgery. Our previous study also
showed that the APACHE II predicted mortality has a very stable
performance in this cohort over the past 10–15 years [17].
Although age and severe co-morbidities are already used to
calculate the APACHE II predicted mortality [15], these two
factors may still have a profound effect on long-term survival over
and beyond the weightings used in the APACHE II predicted
mortality [14,22,23]. As such, both age and Charlson co-morbidity
index were used as separate predictors in additional to the
APACHE II predicted mortality in this prognostic model. These
seven predictors were also chosen because they are often recorded
Table 1. Charlson co-morbidity index component and its
weighting.
Co-morbidity Weighting
Myocardial infarction 1
Congestive heart failure 1
Peripheral vascular disease 1
Cerebrovascular disease 1
Dementia 1
Chronic pulmonary disease 1
Connective tissue disease 1
Peptic ulcer disease 1
Mild liver disease 1
Diabetes mellitus 1
Hemiplegia 2
Moderate or severe renal disease 2
Diabetes with end-organ damage 2
Any tumour 2
Leukemia 2
Lymphoma 2
Moderate to severe liver disease 3
Metastatic solid tumour 6
AIDS 6
doi:10.1371/journal.pone.0003226.t001
PREDICT Model
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possible for other ICUs to validate this model using their data [24].
The proportional hazards assumption of the continuous
predictors in the Cox model was assessed and found to be
acceptable (Figure 1a, 1b, 1c). During the modelling process, we
avoided categorizing continuous predictors [24,25] and allowed a
non-linear relationship with hazard of death using a 6-knot
restricted cubic spline function [25]. The relative contribution of
each predictor was assessed using the chi-square statistic minus the
degrees of freedom [25]. The discrimination performance of the
model was assessed with the c-index, which is a generalization of
the c-statistic or the area under the receiver-operating character-
istic curve, allowing for censored data [25,26]. In this study, a c-
index between 0.70 and 0.80 was regarded as acceptable and a c-
index above 0.80 was regarded as excellent [27]. Using the Design
library in S-PLUS software (version 8.0, 2007. Insightful Corp.,
Seattle, Washington, USA), the c-index was computed and
adjusted for optimism (arising from using the same data to
develop the model and assess its performance) by a bootstrap
technique to penalise for possible over-fitting, with 200 re-samples
and at least 200 patients per risk group [25,28]. The bootstrapping
technique was used in this study instead of splitting the data into
development and validation data set because this method is
regarded as most data ‘efficient’ and accurate in developing a
prognostic model [25]. Model calibration (similarity of predicted
risks and proportions actually dying) was assessed graphically and
used a bootstrap re-sampling to construct a bias-corrected
calibration curve and its slope [25,29]. Nagelkerke’s R
2 (a
generalized measure of the percentage of the variance in survival
accounted for by the model) was computed to assess the overall
performance of the model [25,30]. The performance of the model
was assessed over the full 15 years of follow-up, when follow-up
was restricted to a maximum of 5 years for each patient, and also
when only patients admitted after 1997 were considered.
A nomogram was developed for the model that generates the
median survival time and selected annual survival probabilities by
adding up the scores for each of the seven predictors [25]. The
use of the nomogram and how each predictor may affect a
patient’s long-term prognosis is described for a selection of typical
patient scenarios. In particular, these scenarios were selected to
illustrate how the long-term prognosis of a patient can be
different from the short-term prognosis. Nevertheless, the results
of the nomogram should only be considered as an average
estimate of patients with similar characteristics and not be used
for individual patients.
Results
Characteristics of the cohort
The study cohort consisted of a heterogeneous group of
critically ill patients, with elective surgery including heart valve
surgery, urology, gastrointestinal and spinal surgery accounting for
36.2% of all ICU admissions. The emergency admissions consisted
of patients with multiple trauma (8.5%), isolated head trauma
(2.5%), acute myocardial infarction, congestive heart failure,
cardiac arrhythmias, or cardiogenic shock (7.4%), hypovolemic
or hemorrhagic shock (0.8%), drug overdoses (7.2%), subarach-
noid or intracranial hemorrhage (5.1%), sepsis (4.3%), pneumonia
or aspiration (3.7%), obstructive airway diseases (2.1%), cardiore-
spiratory arrest (4.0%), gastrointestinal hemorrhage, perforation or
obstruction (2.4%), and other medical and surgical emergencies.
Details of this cohort including demographic factors, co-morbid-
ities, severity of acute illness, and the length of ICU and hospital
stay are described in Table 2.
Figure 1. The proportional hazards assumption of the predictors in the Cox model was assessed by plotting the logarithm of the
negative logarithm of the Kaplan Meier survivor estimates and the assumption was found to be acceptable for the three pre-
selected continuous predictors; APACHE II predicted mortality, Charlson co-morbidity index, and age. (a) Graph assessing the
proportionality of hazards associated with severity of acute illness measured by the APACHE II predicted mortality risk categories (0–20%, 20–40%,
40–60%, 60–80%, 80–100%). (b) Graph assessing the proportionality of hazards associated with co-morbidities measured by Charlson co-morbidity
index categories (0, 1, 2, 3, 4–5, .5). (c) Graph assessing the proportionality of hazards associated with age measured by age categories (16–30, 30–
50, 50–60, 60–70, 70–80, .80 years old)
doi:10.1371/journal.pone.0003226.g001
PREDICT Model
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Among all the seven pre-selected predictors in the model, age
(50%), co-morbidity as measured by Charlson co-morbidity index
(27%), and severity of acute illness as measured by the APACHE
II predicted mortality (20%) made the strongest contributions in
predicting survival time (Figure 2). After adjusting for other
predictors, the log hazard of death increased linearly with age,
Charlson co-morbidity index, and the number of days of
vasopressor or inotropic therapy, mechanical ventilation, or
hemofiltration therapy (Figure 3). The relationship between the
APACHE II predicted mortality and log hazard of death was non-
linear with a steep effect when the APACHE II predicted mortality
was less than 10% and a smaller effect when it was more than
10%. The estimated (adjusted) hazard ratios for the seven
predictors are summarized in Figure 4.
Clinical Application of the Model
Figure 5 presents the model in the form of a nomogram that
provides the median survival time and long-term survival
probabilities corresponding to a particular total score. The total
score for a patient is obtained by adding up the scores for each of
the seven predictors. We use the following hypothetical but typical
patients to illustrate how the nomogram is used and how the short-
term prognosis of a patient can be quite different from the long-
term prognosis.
Patient A:
A 40-year old male, without pre-existing co-morbidities (ie
Charlson co-morbidity index=0), was admitted to the ICU
because of septic shock with an APACHE II predicted mortality of
80%. He required vasopressor or inotropic therapy, mechanical
ventilation, and hemofiltration therapy during the first 5 days in
the ICU.
The gender of this patient scores 5 points, age scores 28 points,
Charlson co-morbidity scores zero points, the APACHE II
predicted mortality or risk scores 30 points, 5 days of vasopressor
or inotropic therapy scores 7 points, 5 days of mechanically
ventilation scores 15 points, and 5 days of hemofiltration scores 20
points. The total score of this patient is therefore 105 which gives
an estimated median survival time of about 4 years, .70% 1-year
survival probability, .50% 3-year survival probability, .45% 5-
year survival probability, and .20% 10-year survival probability.
Patient B:
A 70-year old female, with chronic obstructive airway disease
and non-insulin dependent diabetes mellitus with no end-organ
damage (ie Charlson co-morbidity index=2), was admitted to the
ICU because of severe community acquired pneumonia with an
APACHE II predicted mortality of 30%. She required vasopressor
or inotropic therapy and mechanical ventilation but not
hemofiltration during the first 5 days in the ICU.
The gender of this patient scores zero points, age scores 70
points, Charlson co-morbidity index scores 12 points, the
APACHE II predicted mortality scores 16 points, 5 days of
mechanical ventilation scores 15 points, and 5 days of vasopressor
or inotropic therapy scores 7 points. The total score of this patient
is therefore 120 which gives an estimated median survival time of
about 2 years, 60% 1-year survival probability, 40% 3-year
survival probability, 30% 5-year survival probability, and 10% 10-
year survival probability.
Patient C:
A 80-year old male, with a history of myocardial infarction,
congestive heart failure, peripheral vascular disease, cerebrovas-
cular disease, and dementia (ie Charlson co-morbidity index=5),
was admitted to an ICU with bowel perforation and peritonitis
with an APACHE II predicted mortality of 30%. He required
vasopressor or inotropic therapy and mechanical ventilation but
not hemofiltration during the first 5 days in the ICU.
The gender of this patient scores 5 points, age scores 85 points,
Charlson co-morbidity index scores 30 points, the APACHE II
predicted mortality scores 16 points, 5 days of mechanical
ventilation scores 15 points, and 5 days of vasopressor or inotropic
therapy scores 7 points. The total score of this patient is therefore
158 which gives an estimated median survival time of ,0.5 years,
25% 1-year survival probability, and 10% 3-year survival
probability.
Discrimination and Calibration of the Prognostic Model
The adjusted c-index for this prognostic model was 0.757 (95%
confidence interval 0.745–0.769), Nagelkerke’s R
2 was 0.255 and
the bias-corrected calibration of the model over a 15-year period
was reasonable (slope of the calibration=0.98)(Figure 6). The
Nagelkerke’s R
2 remained unchanged and the adjusted c-index
only increased marginally when the analysis was restricted to a
maximum of 5 years follow up (c-index=0.759, slope=0.97) or
data after 1997 (c-index=0.762, slope of the calibration=0.97).
Table 2. Characteristics of the cohort (n=11,930).
Variables
Mean (median,
standard deviation),
unless stated
otherwise
Age, yrs 53.8 (57.0, 19.0)
Gender (male/female), no. (%) 7489 (62.8)/4441 (37.2)
Elective surgery admission, no. (%) 4318 (36.2)
APACHE II score 13.7 (13.0, 6.8)
APACHE II predicted mortality, % 14.5 (7.0, 17.8)
No. of APACHE co-morbidities 0.1 (0, 0.3)
(a) Cardiovascular, no. (%) 592 (5.0)
(b) Respiratory, no. (%) 210 (1.8)
(c) Renal, no. (%) 109 (0.9)
(d) Immunosuppressed, no. (%) 197 (1.7)
(e) Liver, no. (%) 76 (0.6)
No. of Charlson co-morbidities 0.8 (0, 1.2)
Charlson co-morbidity index 1.0 (0, 1.7)
Length of ICU stay, days 5.6 (3.0, 8.3)
Length of hospital stay, days 20.3 (13.0, 25.9)
No. of patients mechanically ventilated (%)
# 8034 (67.3)
No. of patients on inotrope (%)
# 3921 (32.9)
No. of patients on dialysis (%)
# 608 (5.1)
No. of ICU survivor (%)* 11557 (96.9)
No. of hospital survivor (%)* 11101 (93.1)
No. of survivor/total no. of patients followed up (%)
(a) at 1-year 10334/11101 (93.1)
(b) at 3-year 8031/10019 (80.2)
(c) at 5-year 6109/8212 (74.4)
(d) at 10-year 2609/4238 (61.6)
(e) at 15-year 441/887 (49.7)
#During the first 5 days in ICU.
*Excluding patients died within 5 days of ICU admission.
ICU, intensive care unit.
APACHE, Acute Physiology and Chronic Health Evaluation.
doi:10.1371/journal.pone.0003226.t002
PREDICT Model
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doi:10.1371/journal.pone.0003226.g002
Figure 3. The relationship between relative hazard and each predictor after adjusting for other predictors in the model.
doi:10.1371/journal.pone.0003226.g003
PREDICT Model
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This study showed that age, gender, co-morbidities (Charlson
co-morbidity index), severity of acute illness (the APACHE II
predicted mortality), and duration of intensive care therapy or
organ support within the first 5 days of ICU admission are
important prognostic factors for long-term survival of critically ill
patients. To the best of our knowledge, this new prognostic model
(Predicted Risk, Existing Diseases, and Intensive Care Therapy:
the PREDICT model) is the first preliminary prognostic model
that can be used to estimate the median survival time and long-
term survival probabilities of critically ill patients up to 15 years
after the onset of critical illness.
The current prognostic model has confirmed that age, gender,
co-morbidities, severity of acute illness, and duration of intensive
care therapy or organ failure are important predictors of 6 months
to 5 years survival of hospitalized or critically ill patients
[13,14,19,22,23]. The current model is indeed built on the results
of these previous studies but further extended the significance of
these risk factors in predicting survival of critically ill patients
beyond 6 months to 5 years. This current model also demonstrat-
ed that most of these predictors have a relatively linear relationship
to the long-term survival probability. More importantly, our
results also showed that age and co-morbidities are the most
important determinants of long-term prognosis of critically ill
patients. This latter finding has at least two significant clinical
Figure 4. The estimated (adjusted) hazard ratios and multilevel confidence bars (0.70 as illustrated by the black bar to 0.99 as
illustrated by the orange bar) for the effects of predictors in the model are summarized in the figure below. An increase of 20 years of
age and an increase in Charlson co-morbidity index from 0 to 5 approximately doubled the risk of death. Doubling the APACHE II predicted mortality
from 20% to 40% increased the relative risk of death by about 30 to 40%. Similarly, increased the number of days of intensive care therapy from 1 to 5
increased the relative risk of death by between 10% and 50%.
doi:10.1371/journal.pone.0003226.g004
Figure 5. Nomogram for predicting long-term survival probabilities and median survival time. Note: gender: 2=female, 1=male.
Predicted.mortality=APACHE II predicted mortality in %.
doi:10.1371/journal.pone.0003226.g005
PREDICT Model
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a critically ill patient are different from those that affect short-term
prognosis. Previous evidence suggested that diagnosis and acute
physiological derangement of a patient are most important in
determining hospital survival [15,31]. In our three hypothetical
patients, Patient A has in fact the most severe form of acute critical
illness and worst short-term prognosis. Nevertheless, because this
patient is younger and has no co-morbidities, this patient has a
very reasonable and better long-term prognosis than Patient B and
C. If we use the prognostic model developed by Wright et al. [14]
to estimate the long-term survival of our three hypothetical
patients, Patient B will have the best 5-year prognosis (risk score is
estimated to be 68) followed by Patient C (risk score 75) and then
Patient A (risk score 87). The lack of detailed co-morbidity data
and a heavy emphasis on severity of acute illness in the model
developed by Wright et al. is the most likely explanation why our
results are different from theirs.
Many clinicians may intuitively consider the intensity of organ
failure as very important in affecting a patient’s prognosis [32,33].
Our findings suggest that the effect of acute organ failure on long-
term survival is not strong and mostly captured by age, co-
morbidities, and the APACHE II predicted mortality on admission
to ICU. Our previous studies have also showed that the intensity of
organ failure alone is not as important as the APACHE II score in
predicting hospital mortality [34,35]. Therefore, our findings
suggest that clinicians should be very careful not to place undue
emphasis on the severity of acute illness and intensity of organ
failure when making long-term prognostications of critically ill
patients.
Second, because the contributions by intensive care therapy are
relatively small when compared to age, Charlson co-morbidity
index, and the APACHE II predicted mortality, using the data
after the first 24 to 48 hours of ICU stay is unlikely to
underestimate the final total prediction score significantly (,20
points)(Figure 5). Therefore, early estimation of a slightly
‘optimistic’ long-term survival probability and median survival
time is feasible after the first 24 to 48 hours of ICU stay; and in
patients with either extremes of prognosis, this early estimation is
unlikely to be significantly different from the final prediction by
collecting all data after five days of intensive care therapy.
Nevertheless, the current prognostic model utilizes the APACHE
II predicted mortality after ICU admission as a predictor to
estimate long-term survival, as such, the model cannot be used, in
its current form, as a tool to triage ICU admission.
This study has significant limitations. First, patients’ wishes and
the anticipated quality of life before and after their critical illness
are important factors in making treatment decisions [36,37]. The
median survival time and long-term survival probabilities is only
one of the many factors that patients and clinicians may consider
in making treatment decisions. Furthermore, the c-statistics of this
model is only about 0.76 and this leaves considerable uncertainty
in its applicability in predicting long-term survival of individual
patients. As such, the predicted survival probabilities of this
prognostic model should only be considered as an average estimate
of patients with similar characteristics and should not be used for
individual patients. Second, evidence suggests that combining an
objective prognostic model with physicians’ intuition may improve
the accuracy of outcome prediction [13]. Whether combining this
current prognostic model with physicians’ intuition will improve its
predictive performance further remains uncertain, but this merits
further investigation. Third, although we studied a large cohort of
critically ill patients, and also the case-mix, severity of illness, and
Figure 6. Bootstrap estimate of calibration accuracy for 15-year estimates from the Cox proportional hazards model. Dots
correspond to apparent predictive accuracy and x marks the bootstrap-corrected estimates.
doi:10.1371/journal.pone.0003226.g006
PREDICT Model
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ICUs in Australia [38], validation of this model by other ICUs that
have access to data linkage is essential to assess its generalizability.
Finally, although the APACHE II prognostic model is still widely
used for risk adjustment purposes in many ICUs [39,40], it is
possible that using newer prognostic models instead of the
APACHE II prognostic model may improve our current model
[41]. Similarly, the performance of the current model may be
improved if we consider more predictors in the model although
this will also increase the complexity of the model. In this regard,
we hope that the PREDICT model developed in this study will be
of value to others who aim to develop a new prognostic model to
enhance our understanding of long-term survival of critically ill
patients.
In summary, Age, gender, co-morbidities, severity of acute
illness, and the intensity and duration of intensive care therapy can
be used to estimate long-term survival of critically ill patients. Age
and co-morbidity are the most important determinants of the long-
term prognosis of critically ill patients. The current prognostic
model, the PREDICT model, provides a framework for
prognostications and risk adjustment when long-term survival of
critically ill patients is considered.
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